Biotech News
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
investors.atyrpharma.com2026-05-06 15:06 EST
Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025. SAN DIEGO , Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged